A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Clinical trial NCT03899792 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03899792
Sponsor: Eli Lilly and Company
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Medullary Thyroid Cancer Infantile Myofibromatosis Infantile Fibrosarcoma Papillary Thyroid Cancer Soft Tissue Sarcoma

Start date: 2019-06-13
Primary completion: 2024-11-08
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.